FSTX - F-star Therapeutics falls for a second day as CFIUS deadline set to expire

• F-star Therapeutics ( NASDAQ: FSTX ) dropped 3.3% after falling 7% Friday as a deadline for a national security review of its planned sale to Sino-Biopharma ( OTCPK:SBHMY ) is set to expire on Monday.
• F-star ( FSTX ) disclosed last month that a CFIUS review of its sale to Sino-Biopharma ( OTCPK:SBHMY ) moved into an extended review , which was disclosed on Sept. 15. The share s were weaker on Friday amidst a A New York Times article from Thursday that reported that the U.S. may extend export control restrictions it has issued in China to areas such as biotechnology.
• The extended CFIUS review was not seen as unusual or a surprise by the parties, according to a Dealreporter item from Oct. 11. InvoX’s advanced platform using AI-driven digital solutions was said to be an area of concern for the regulator.
• F-Star ( FSTX ) and Sini-Biopharma didn't immediately return Seeking Alpha email request for comment on Monday.
• China's Sino Biopharmaceutical's ( OTCPK:SBHMY ) unit invoX Pharma agreed to acquire F-star Therapeutics ( FSTX ) in a $161M all-cash deal in late June. The deal is expected to close in H2 2022.

For further details see: